Literature DB >> 22128783

Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies.

Christina M Rodrigo1, Regina Cencic, Stéphane P Roche, Jerry Pelletier, John A Porco.   

Abstract

The rocaglates/rocaglamides are a class of natural products known to display potent anticancer activity. One such derivative, silvestrol, has shown activity comparable to taxol in certain settings. Here, we report the synthesis of various rocaglamide analogues and identification of a hydroxamate derivative (-)-9 having activity similar to silvestrol in vitro and ex vivo for inhibition of protein synthesis. We also show that (-)-9 synergizes with doxorubicin in vivo to reduce Eμ-Myc driven lymphomas.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22128783      PMCID: PMC3263355          DOI: 10.1021/jm201263k

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  18 in total

1.  Design and synthesis of potent Gram-negative specific LpxC inhibitors.

Authors:  U Faruk Mansoor; Dilrukshi Vitharana; Panduranga Adulla Reddy; Dayna L Daubaras; Paul McNicholas; Peter Orth; Todd Black; M Arshad Siddiqui
Journal:  Bioorg Med Chem Lett       Date:  2010-12-28       Impact factor: 2.823

2.  Enantioselective synthesis of the complex rocaglate (-)-silvestrol.

Authors:  Baudouin Gerard; Regina Cencic; Jerry Pelletier; John A Porco
Journal:  Angew Chem Int Ed Engl       Date:  2007       Impact factor: 15.336

3.  Gold-catalyzed halogenation of aromatics by N-halosuccinimides.

Authors:  Fanyang Mo; Jerry Mingtao Yan; Di Qiu; Fei Li; Yan Zhang; Jianbo Wang
Journal:  Angew Chem Int Ed Engl       Date:  2010-03-08       Impact factor: 15.336

4.  Design and evaluation of hydroxamate derivatives as metal-mediated inhibitors of a protein tyrosine kinase.

Authors:  Xianfeng Gu; Yuehao Wang; Anil Kumar; Guofeng Ye; Keykavous Parang; Gongqin Sun
Journal:  J Med Chem       Date:  2006-12-14       Impact factor: 7.446

5.  Novel flavaglines displaying improved cytotoxicity.

Authors:  Frédéric Thuaud; Nigel Ribeiro; Christian Gaiddon; Thierry Cresteil; Laurent Désaubry
Journal:  J Med Chem       Date:  2010-12-13       Impact factor: 7.446

6.  Silvestrol regulates G2/M checkpoint genes independent of p53 activity.

Authors:  Qiuwen Mi; Soyoung Kim; Bang Yeon Hwang; Bao-Ning Su; Heebyung Chai; Zarema H Arbieva; A Douglas Kinghorn; Steven M Swanson
Journal:  Anticancer Res       Date:  2006 Sep-Oct       Impact factor: 2.480

7.  Design, synthesis, and biological evaluation of simplified alpha-keto heterocycle, trifluoromethyl ketone, and formyl substituted folate analogues as potential inhibitors of GAR transformylase and AICAR transformylase.

Authors:  Thomas H Marsilje; Michael P Hedrick; Joel Desharnais; Ali Tavassoli; Yan Zhang; Ian A Wilson; Stephen J Benkovic; Dale L Boger
Journal:  Bioorg Med Chem       Date:  2003-10-01       Impact factor: 3.641

8.  Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A.

Authors:  Marie-Eve Bordeleau; Ayaka Mori; Monika Oberer; Lisa Lindqvist; Louisa S Chard; Tatsuo Higa; Graham J Belsham; Gerhard Wagner; Junichi Tanaka; Jerry Pelletier
Journal:  Nat Chem Biol       Date:  2006-03-12       Impact factor: 15.040

9.  Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.

Authors:  Frédéric Thuaud; Yohann Bernard; Gülen Türkeri; Ronan Dirr; Geneviève Aubert; Thierry Cresteil; Aurélie Baguet; Catherine Tomasetto; Yuri Svitkin; Nahum Sonenberg; Canan G Nebigil; Laurent Désaubry
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

Review 10.  Targeting the eukaryotic translation initiation factor 4E for cancer therapy.

Authors:  Jeremy R Graff; Bruce W Konicek; Julia H Carter; Eric G Marcusson
Journal:  Cancer Res       Date:  2008-02-01       Impact factor: 12.701

View more
  40 in total

Review 1.  Chemical probes and drug leads from advances in synthetic planning and methodology.

Authors:  Christopher J Gerry; Stuart L Schreiber
Journal:  Nat Rev Drug Discov       Date:  2018-04-13       Impact factor: 84.694

2.  Tracing MYC Expression for Small Molecule Discovery.

Authors:  Jutta Steinberger; Francis Robert; Maxime Hallé; David E Williams; Regina Cencic; Neha Sawhney; Dylan Pelletier; Philip Williams; Yasuhiro Igarashi; John A Porco; Abimael D Rodriguez; Brigitte Kopp; Brian Bachmann; Raymond J Andersen; Jerry Pelletier
Journal:  Cell Chem Biol       Date:  2019-03-14       Impact factor: 8.116

3.  Enantioselective photocycloaddition of 3-hydroxyflavones: total syntheses and absolute configuration assignments of (+)-ponapensin and (+)-elliptifoline.

Authors:  Neil J Lajkiewicz; Stéphane P Roche; Baudouin Gerard; John A Porco
Journal:  J Am Chem Soc       Date:  2012-07-25       Impact factor: 15.419

4.  A photochemical flow reactor for large scale syntheses of aglain and rocaglate natural product analogues.

Authors:  Han Yueh; Qiwen Gao; John A Porco; Aaron B Beeler
Journal:  Bioorg Med Chem       Date:  2017-06-11       Impact factor: 3.641

Review 5.  Rocaglamide, silvestrol and structurally related bioactive compounds from Aglaia species.

Authors:  Li Pan; John L Woodard; David M Lucas; James R Fuchs; A Douglas Kinghorn
Journal:  Nat Prod Rep       Date:  2014-05-02       Impact factor: 13.423

6.  Rocaglates as dual-targeting agents for experimental cerebral malaria.

Authors:  David Langlais; Regina Cencic; Neda Moradin; James M Kennedy; Kodjo Ayi; Lauren E Brown; Ian Crandall; Michael J Tarry; Martin Schmeing; Kevin C Kain; John A Porco; Jerry Pelletier; Philippe Gros
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-20       Impact factor: 11.205

7.  Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma.

Authors:  Salomon Manier; Daisy Huynh; Yu J Shen; Jia Zhou; Timur Yusufzai; Karma Z Salem; Richard Y Ebright; Jiantao Shi; Jihye Park; Siobhan V Glavey; William G Devine; Chia-Jen Liu; Xavier Leleu; Bruno Quesnel; Catherine Roche-Lestienne; John K Snyder; Lauren E Brown; Nathanael Gray; James Bradner; Luke Whitesell; John A Porco; Irene M Ghobrial
Journal:  Sci Transl Med       Date:  2017-05-10       Impact factor: 17.956

8.  eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer.

Authors:  Tim Kong; Yibo Xue; Regina Cencic; Xianbing Zhu; Anie Monast; Zheng Fu; Virginie Pilon; Veena Sangwan; Marie-Christine Guiot; William D Foulkes; John A Porco; Morag Park; Jerry Pelletier; Sidong Huang
Journal:  Mol Cancer Ther       Date:  2019-08-08       Impact factor: 6.261

9.  Amidino-Rocaglates: A Potent Class of eIF4A Inhibitors.

Authors:  Jennifer Chu; Wenhan Zhang; Regina Cencic; William G Devine; Dmitri Beglov; Thomas Henkel; Lauren E Brown; Sandor Vajda; John A Porco; Jerry Pelletier
Journal:  Cell Chem Biol       Date:  2019-09-10       Impact factor: 8.116

10.  Evidence for a functionally relevant rocaglamide binding site on the eIF4A-RNA complex.

Authors:  Heather Sadlish; Gabriela Galicia-Vazquez; C Gregory Paris; Thomas Aust; Bhupinder Bhullar; Lena Chang; Stephen B Helliwell; Dominic Hoepfner; Britta Knapp; Ralph Riedl; Silvio Roggo; Sven Schuierer; Christian Studer; John A Porco; Jerry Pelletier; N Rao Movva
Journal:  ACS Chem Biol       Date:  2013-05-07       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.